Amneal Pharmaceuticals, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001723128-26-000020
- Form type
- 10-Q
- CIK
- 0001723128
- Primary document
- https://www.sec.gov/Archives/edgar/data/1723128/000172312826000020/amrx-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amneal Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $722.5M | - | - |
| Cost Of Revenue | $402.4M | - | - |
| Gross Profit | $320.1M | - | - |
| Operating Income | $141.8M | - | - |
| Net Income | $62.3M | - | - |
| Eps Basic | 0.2 | - | - |
| Eps Diluted | 0.19 | - | - |
| Cash And Equivalents | $197.7M | - | - |
| Total Assets | $3.5B | - | - |
| Shareholders Equity | $-45.4M | - | - |
| Operating Cash Flow | $-26.7M | - | - |
| Capital Expenditures | $8.2M | - | - |